SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) of the
SECURITIES
EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 27, 2024
(
(Exact
Name of Registrant as Specified in Charter)
| |
| |
| (State or other jurisdiction of Nika Pharmaceuticals, Inc.) | (Commission File Number) | (IRS Employer Identification No.) |
(Address
of principal executive offices) (Zip code)
(
Registrant's telephone number, including area
code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Section 2 – Financial Information
Item 2.01 Completion of Acquisition of Assets.
On August 18, 2024, based on recommendation of Clifford Redekop, officer and director, the board of directors found it in the Nika Pharmaceuticals Inc.’s best interest to cancel the acquisition of Nika Pharmaceuticals, Ltd., UIC: 175420503 that was made effective on May 9, 2024 and disclosed via Form 8-K on May 10, 2024. The procedure to return the 100% to Dimitar Slavchev Savov, who is an officer and director of Nika Pharmaceluticals, Inc. and general manager of Nika Pharmaceuticals, Ltd., was initiated on August 19, 2024 and was made effective on August 23, 2024, resulting in Nika Pharmaceuticals, Ltd. no longer being a wholly owned subsidiary of Nika Pharmaceuticals, Inc. As a result, Nika Pharmaceuticals, Inc. no longer practically owns 99.99% in Nika Europe, Ltd. and is no longer the beneficial owner of the factory building and land disclosed in the aforementioned Form 8-K dated May 10, 2024.
Section 4 - Matters Related to Accountants and Financial Statements Item 4.01 Changes in Registrant’s Certifying Accountant.
On August 21, 2024 Nika Pharmaceuticals, Inc.’s independent accountant Fruci & Associates II, PLLC tendered its resignation. The members of the board of directors have discussed the issue with the former independent accountant, and Nika Pharmaceuticals, Inc. has authorized the former independent accountant to respond fully to the inquiries of the successor accountant concerning historical data.
As the situation was unexpected, Nika Pharmaceuticals, Inc. is still looking for a new firm to serve as the independent accountant to audit the company’s financial statements and will strive to publish its 10-Q as early as possible.
Item 9.01 Exhibits
(d) Exhibits
| 23.1 | Consent Letter by Fruci & Associates II, PLLC |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, hereunto duly authorized.
| NIKA PHARMACEUTICALS, INC. | ||
| Dated: August 27, 2024 | By: | /s/ Dimitar SlavchevSavov |
| Dimitar SlavchevSavov | ||
| Chief Executive Officer, | ||
| Director | ||